Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with
hematological malignancies and autoimmune diseases. The most commonly employed …

Abstract Purpose of Review Passive immunotherapy with therapeutic monoclonal antibodies
(mAbs) has revolutionized the treatment of cancer, especially hematological malignancies …

With the widespread use of therapeutic monoclonal antibodies in the treatment of patients
with cancer, resistance to these agents has become a major issue. Preclinical models of …

In 1997, the first monoclonal antibody (MoAb), the chimeric anti‐CD20 molecule rituximab,
was approved by the US Food and Drug administration for use in cancer patients. Since …

Over the past decade, the clinical utility of monoclonal antibodies has been realized and
antibodies are now a mainstay for the treatment of cancer. Antibodies have the unique …

Monoclonal antibodies have yet considerably modified the field of clinical oncology. The
growing knowledge of key cellular pathways in tumor induction and progression, targeted …

Complement-dependent cytotoxicity (CDC) is one of the effector mechanisms mediated by
therapeutic anticancer monoclonal antibodies (mAbs). However, the efficacy of antibodies is …

PURPOSE To review recent advances in the development and clinical roles of monoclonal
antibody (MoAb)-based therapies in the treatment of hematologic malignancies. DESIGN A …

Since the approval of rituximab in 1997, monoclonal antibodies have come to play an
important role in the therapy of hematological malignancies. Rituximab, gemtuzumab …

During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …